Hubert Allen - Abbott Laboratories Executive VP, General Counsel and Secretary
| ABT Stock | MXN 2,282 113.00 0.12% |
EVP
Mr. Hubert L. Allen is Executive Vice President, General Counsel and Secretary of the Company. From 2010 to 2012 Divisional Vice President and Associate General Counsel, Established Pharmaceuticals 2009 to 2010 Divisional Vice President and Associate General Counsel, Proprietary Pharmaceuticals 2007 to 2009 Section Head, Legal, Abbott Nutrition. He is Elected Corporationrationrate Officer in 2012 since 2013.
| Age | 57 |
| Tenure | 12 years |
| Phone | 224 667 6100 |
| Web | https://www.abbott.com |
Hubert Allen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Hubert Allen against Abbott Laboratories stock is an integral part of due diligence when investing in Abbott Laboratories. Hubert Allen insider activity provides valuable insight into whether Abbott Laboratories is net buyers or sellers over its current business cycle. Note, Abbott Laboratories insiders must abide by specific rules, including filing SEC forms every time they buy or sell Abbott Laboratories'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Hubert Allen over a month ago Disposition of 131360 shares by Hubert Allen of Abbott Laboratories at 38.4 subject to Rule 16b-3 |
Abbott Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.0882 % which means that it generated a profit of $0.0882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1928 %, meaning that it generated $0.1928 on every $100 dollars invested by stockholders. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.Abbott Laboratories has accumulated 17.3 B in total debt with debt to equity ratio (D/E) of 64.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Abbott Laboratories has a current ratio of 1.55, which is within standard range for the sector. Debt can assist Abbott Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, Abbott Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abbott Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abbott to invest in growth at high rates of return. When we think about Abbott Laboratories' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | EVP Age | ||
| Brian Woram | KB Home | 62 | |
| Albert Praw | KB Home | 74 | |
| Glen Hauenstein | Delta Air Lines | 62 | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0882 |
Abbott Laboratories Leadership Team
Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Leinenweber, Licensing Relations | ||
| Robert Ford, Senior Vice President Diabetes Care. | ||
| James Young, VP Officer | ||
| Mary Moreland, Ex HR | ||
| Elaine Leavenworth, VP Officer | ||
| Robert Funck, Vice President Controller | ||
| Daniel Salvadori, Senior Vice President Established Pharmaceuticals, Latin America. | ||
| Andrea Wainer, Ex Diagnostics | ||
| Hubert Allen, Executive VP, General Counsel and Secretary | ||
| Melissa Brotz, VP Marketing |
Abbott Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0882 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 3.99 T | |||
| Shares Outstanding | 1.74 B | |||
| Shares Owned By Insiders | 0.73 % | |||
| Shares Owned By Institutions | 75.70 % | |||
| Price To Book | 5.44 X | |||
| Price To Sales | 85.65 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Abbott Stock Analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.